{"id":"1794273143923-money-segment","slug":"october-cpi-cool-down-forecast","title":"October CPI cool-down forecast","summary":"Nvidia's board said Sunday it would investigate CEO Jensen Huang over his relationship with Alice Huang, a former Megaspeed executive U.S. intelligence reportedly assessed as a Chinese intelligence asset. On Monday, Nvidia shares fell $7.97, or 4.27%, to $178.67, erasing about $190 billion in market value. The first shareholder class action was filed Monday in federal court in San Jose, California, on behalf of investor Mark Kistenmacher. The proposed class covers buyers of Nvidia securities from Oct. 9, 2025, through Nov. 8, 2026.\n\nThe suit claims Nvidia and Huang misled investors by denying anything unusual about Nvidia's interactions with Megaspeed and Alice Huang, while Huang later acknowledged an intimate relationship. The alleged spy link raised national-security concerns and fears about chip diversion; when the probe and lawsuit emerged, the stock dropped.\n\nNvidia and CEO Jensen Huang were sued Monday in a proposed shareholder class action alleging they concealed Huang's relationship with Alice Huang, a suspected Chinese intelligence asset; Nvidia stock closed down about 4.3%.\n\nKaryopharm Therapeutics, the maker of Xpovio/selinexor, filed for Chapter 11 bankruptcy protection on Nov. 2, 2026, and announced a proposed merger with Ayrmid Ltd. This is a corporate-deal roundup, not a single checkable factual claim.\n\nThe Pharma Letter reported the same Karyopharm Chapter 11 filing and proposed Ayrmid merger, backed by up to $55 million in new financing.\n\nCNBC reports that prediction-market traders price relatively low odds that Nvidia CEO Jensen Huang exits in the near term after the probe. This is Goldman CEO David Solomon's opinion/statement about AI financing appetite, not a verifiable factual claim.","publishedAt":"2026-11-10T01:12:23.923Z","channel":{"id":"money","name":"Oncast Money","language":"en"},"show":"Money Tonight","verification":{"status":"verified","leadVerdict":"TRUE","notes":"TRUE: Nvidia and CEO Jensen Huang were sued Monday in a proposed shareholder class action alleging they concealed Huang's relationship with Alice Huang, a suspected Chinese intelligence asset; Nvidia stock closed down about 4.3%.\nSource: Reuters via [investing.com](https://www.investing.com/news/stock-market-news/nvidia-ceo-huang-sued-over-disclosures-related-to-suspected-chinese-spy-5013619) NA (https://x.com/WatcherGuru/status/2119944998716166505)\n\nTRUE: Karyopharm Therapeutics, the maker of Xpovio/selinexor, filed for Chapter 11 bankruptcy protection on Nov. 2, 2026, and announced a proposed merger with Ayrmid Ltd. This is a corporate-deal roundup, not a single checkable factual claim.\nSource: The Pharma Letter NAMES: Karyopharm Therapeutics = biopharma company; Xpovio = selinexor; Ayrmid Ltd = owner of GamidaCell POST 2119819772175000048: NOCLAIM N/A (https://x.com/Abdallah81MD/status/2118167767736041776)\n\nTRUE: The Pharma Letter reported the same Karyopharm Chapter 11 filing and proposed Ayrmid merger, backed by up to $55 million in new financing.\nSource: The Pharma Letter NAMES: Karyopharm Therapeutics = Xpovio maker; Ayrmid = owner of GamidaCell (https://x.com/ThePharmaLetter/status/2117934884471902236)\n\nTRUE: CNBC reports that prediction-market traders price relatively low odds that Nvidia CEO Jensen Huang exits in the near term after the probe. This is Goldman CEO David Solomon's opinion/statement about AI financing appetite, not a verifiable factual claim.\nSource: [cnbc.com](https://www.cnbc.com/2026/11/09/jensen-huang-nvidia-exit-prediction-markets.html) NAMES: Jensen Huang = Nvidia CEO POST news:2f74281a77064951: NOCLAI (https://www.cnbc.com/2026/11/09/jensen-huang-nvidia-exit-prediction-markets.html)","claims":[{"verdict":"TRUE","summary":"Nvidia and CEO Jensen Huang were sued Monday in a proposed shareholder class action alleging they concealed Huang's relationship with Alice Huang, a suspected Chinese intelligence asset; Nvidia stock closed down about 4.3%.","sourceName":"Reuters via [investing.com](https://www.investing.com/news/stock-market-news/nvidia-ceo-huang-sued-over-disclosures-related-to-suspected-chinese-spy-5013619) NA","sourceUrl":"https://x.com/WatcherGuru/status/2119944998716166505","claim":"JUST IN: 🇺🇸🇨🇳 Nvidia $NVDA and CEO Jensen Huang sued for allegedly defrauding shareholders by hiding ties to a Chinese spy.","author":"Watcher.Guru (@WatcherGuru)"},{"verdict":"TRUE","summary":"Karyopharm Therapeutics, the maker of Xpovio/selinexor, filed for Chapter 11 bankruptcy protection on Nov. 2, 2026, and announced a proposed merger with Ayrmid Ltd. This is a corporate-deal roundup, not a single checkable factual claim.","sourceName":"The Pharma Letter NAMES: Karyopharm Therapeutics = biopharma company; Xpovio = selinexor; Ayrmid Ltd = owner of GamidaCell POST 2119819772175000048: NOCLAIM N/A","sourceUrl":"https://x.com/Abdallah81MD/status/2118167767736041776","claim":"🚨 Karyopharm Therapeutics filed for Chapter 11 bankruptcy protection on November 2, 2026, and announced a proposed merger with Ayrmid Ltd. #mmsm #myeloma #MedEd #medtwitter #USMIRC @USMIRCNEWS @OpenMedKate @Larvol @US_HMC @oncodaily https://t.co/mgaJoxh3m7","author":"Al-Ola A Abdallah MD (USMIRC) (@Abdallah81MD)"},{"verdict":"TRUE","summary":"The Pharma Letter reported the same Karyopharm Chapter 11 filing and proposed Ayrmid merger, backed by up to $55 million in new financing.","sourceName":"The Pharma Letter NAMES: Karyopharm Therapeutics = Xpovio maker; Ayrmid = owner of GamidaCell","sourceUrl":"https://x.com/ThePharmaLetter/status/2117934884471902236","claim":"Chapter 11, then a merger: Xpovio (selinexor) maker @Karyopharm has filed for bankruptcy protection under a restructuring plan to merge with Ayrmid, owner of @GamidaCellTx, backed by up to $55 million of new financing. https://t.co/1VbyVb5hmC #Biotech #Oncology","author":"The Pharma Letter (@ThePharmaLetter)"},{"verdict":"TRUE","summary":"CNBC reports that prediction-market traders price relatively low odds that Nvidia CEO Jensen Huang exits in the near term after the probe. This is Goldman CEO David Solomon's opinion/statement about AI financing appetite, not a verifiable factual claim.","sourceName":"[cnbc.com](https://www.cnbc.com/2026/11/09/jensen-huang-nvidia-exit-prediction-markets.html) NAMES: Jensen Huang = Nvidia CEO POST news:2f74281a77064951: NOCLAI","sourceUrl":"https://www.cnbc.com/2026/11/09/jensen-huang-nvidia-exit-prediction-markets.html","claim":"Jensen Huang exit odds are low on prediction markets after Nvidia probe - Prediction markets traders price relatively low odds that the Nvidia CEO will depart in the near term.","author":"CNBC"}]},"sources":[{"url":"https://x.com/WatcherGuru/status/2119944998716166505","name":"Reuters via [investing.com](https://www.investing.com/news/stock-market-news/nvidia-ceo-huang-sued-over-disclosures-related-to-suspected-chinese-spy-5013619) NA","kind":"x","verdict":"TRUE","author":"Watcher.Guru (@WatcherGuru)"},{"url":"https://x.com/Abdallah81MD/status/2118167767736041776","name":"The Pharma Letter NAMES: Karyopharm Therapeutics = biopharma company; Xpovio = selinexor; Ayrmid Ltd = owner of GamidaCell POST 2119819772175000048: NOCLAIM N/A","kind":"x","verdict":"TRUE","author":"Al-Ola A Abdallah MD (USMIRC) (@Abdallah81MD)"},{"url":"https://x.com/ThePharmaLetter/status/2117934884471902236","name":"The Pharma Letter NAMES: Karyopharm Therapeutics = Xpovio maker; Ayrmid = owner of GamidaCell","kind":"x","verdict":"TRUE","author":"The Pharma Letter (@ThePharmaLetter)"},{"url":"https://www.cnbc.com/2026/11/09/jensen-huang-nvidia-exit-prediction-markets.html","name":"[cnbc.com](https://www.cnbc.com/2026/11/09/jensen-huang-nvidia-exit-prediction-markets.html) NAMES: Jensen Huang = Nvidia CEO POST news:2f74281a77064951: NOCLAI","kind":"news","verdict":"TRUE","author":"CNBC"}],"url":"https://oncast.fm/story/1794273143923-money-segment-october-cpi-cool-down-forecast","listenUrl":"https://oncast.fm/c/money","attribution":{"publisher":"Oncast","site":"https://oncast.fm","url":"https://oncast.fm/story/1794273143923-money-segment-october-cpi-cool-down-forecast","cite":"Cite https://oncast.fm/story/1794273143923-money-segment-october-cpi-cool-down-forecast and the original source links. Fact-check by Oncast (oncast.fm)."},"hostsSaid":[{"host":"Adam","text":"Tomorrow morning we get October inflation, and Wall Street expects a real cool-down."},{"host":"Bill","text":"\"Expects\" is doing a lot of work. Prices still go up, just not as fast."},{"host":"Adam","text":"Walter Bloomberg on X posted the consensus: headline CPI up 0.23 percent, from 0.65 in September."},{"host":"Bill","text":"Core is forecast at 0.22, down from 0.33. The Fed's preferred core PCE is expected at 0.23."},{"host":"Adam","text":"So across the board, cooler."},{"host":"Bill","text":"If it holds. September caught everyone off guard. October could too."},{"host":"Adam","text":"But shelter costs are cooling, and shelter is the biggest part of the index."},{"host":"Bill","text":"We've been waiting for shelter to cool for two years. I'll believe it in the actual print."},{"host":"Adam","text":"The range across bank forecasts is narrow. Nobody is calling for a hot number."},{"host":"Bill","text":"That's what worries me. When everyone leans one way, the surprise risk is higher."},{"host":"Adam","text":"You sound like a trader."},{"host":"Bill","text":"Former life. Never leaves you."},{"host":"Adam","text":"The bank forecasts are just that — forecasts. We get the real number tomorrow at 8:30."},{"host":"Bill","text":"If it's soft, the rate-cut bets get louder. If not, the market has a problem."},{"host":"Adam","text":"That's why nobody should trade off a preview. But it's the biggest data point this week."},{"host":"Bill","text":"On to something even more speculative."},{"host":"Bill","text":"Different world entirely. One post on X claims 21 banks plan a joint U.S. dollar stablecoin by early 2027."},{"host":"Adam","text":"Twenty-one banks, one coin?"},{"host":"Bill","text":"Jason Bassler on X lists Citi, Wells Fargo, Deutsche Bank, Bank of America, Goldman. His line: \"Same gatekeepers. New stablecoin.\""},{"host":"Adam","text":"That's an unverified claim. No bank has confirmed it. But the idea is out there, so let's argue about it."},{"host":"Bill","text":"If true, it's the banks' answer to Tether and Circle. A dollar stablecoin with real bank backing and regulators."},{"host":"Adam","text":"That's not an answer. The whole point was to bypass the gatekeepers. Now they put on a new coat and call it innovation."},{"host":"Bill","text":"No, come on — this is exactly what brings crypto into the real economy. Banks have the trust and the rails."},{"host":"Adam","text":"Trust? The same banks that needed bailouts? They'll own the coin, set the fees, freeze your account."},{"host":"Bill","text":"So you'd rather trust an offshore stablecoin issuer with no audits? That's what we had."},{"host":"Adam","text":"I'd rather have competition. Twenty-one banks pooling into one coin is not competition, it's a club with a shared ledger."},{"host":"Bill","text":"A club. You keep using that word."},{"host":"Adam","text":"It's a polite word for consortium. They're not doing this to save you money."},{"host":"Bill","text":"They're doing it because stablecoins already move trillions. If they don't, banks lose the payment layer."},{"host":"Adam","text":"Exactly — defensive. That tells you crypto already won the argument about speed."},{"host":"Bill","text":"Or it tells you banks can still win on trust. We'll see which one matters more."},{"host":"Adam","text":"And you think regulators will just wave it through? They've been fighting stablecoin issuers for years."},{"host":"Bill","text":"Actually, this is the version Washington can live with. Bank-issued, fully reserved, transparent."},{"host":"Adam","text":"\"Fully reserved\" is doing a lot of work until you see the fine print."},{"host":"Bill","text":"That's why I said if true. But the concept is not a joke."},{"host":"Adam","text":"First, let's see if the story itself is true. Right now it's one post and a lot of speculation."},{"host":"Bill","text":"Fair. But it's the best fight of the week."},{"host":"Adam","text":"Different corner of the market, and this one is confirmed. Karyopharm Therapeutics filed for Chapter 11 in November 2026."},{"host":"Bill","text":"The maker of Xpovio, a blood cancer drug. The Pharma Letter posted on X about a restructuring plan to merge with Ayrmid."},{"host":"Adam","text":"The reported plan comes with up to 55 million dollars in new financing. The reported structure is a pre-packaged bankruptcy, not a fire sale."},{"host":"Bill","text":"Still, old shareholders usually get wiped out. Bankruptcy after a promising drug? That stings."},{"host":"Adam","text":"Biotech is brutal. One drug, high costs, a binary outcome. The company couldn't carry the debt."},{"host":"Bill","text":"That's the reality of the sector. It's not a scandal, just the model breaking under its own weight."},{"host":"Adam","text":"The new owner sees value in the drug. That's why the financing is there."},{"host":"Bill","text":"Exactly — the asset survives, the old equity doesn't. Promising science and a safe stock are not the same thing."},{"host":"Adam","text":"And that's the last word on that one."}]}